Achieve Life Sciences, Inc. announced its financial results for Q4 and the year-end 2024, while reaffirming plans to submit a new drug application (NDA) for cytisinicline, a treatment for nicotine ...
Q1 2025 Management View CEO Rick Stewart stated that "Achieve is on track to submit the NDA for cytisinicline next month." He emphasized that "all internal resources are now focused on a successful ...
Achieve Life Sciences, Inc. (ACHV) has done well to advance its main clinical program, which would be the use of its drug cytisinicline for smoking cessation. The company has had an extensive program, ...
SEATTLE and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results